A moderately,long-acting mydriatic and cycloplegic for refraction and in the treatment of inflammatory conditions of the uveal tract. For pre- and post-operative states when mydriasis is required. Use as an optical aid in some case of axial lens opacities.
Mydriatic and Cycloplegic agents
Homatropine is a competitive muscarinic receptor antagonist with a bulky aromatic group in place of the acetyl group of acetylcholine. It is expected to act in similar manner as atropine, producing similar parasympatholytic effects. By blocking muscarinic receptors and cholinergic signalling pathways, homatropine blocks the response of the iris sphincter muscle and cause the pupil to become unresponsive to light upon dilation or mydriasis. It also blocks the accommodative muscle of the ciliary body to cholinergic stimulation.
For refraction,instill one or two drops topically in the eye(s). May be repeated in five to ten minutes if necessary. For uveitis,instill one or two drops topically up to every three to four hours. Individuals with heavily pigmented irides may require larger doses. Only the 2% strength should be used in pediatric patients
Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.
Contraindicated in persons with primary glaucoma or a tendency towards glaucoma,e.g.,narrow anterior chamber angle,and in those persons showing hypersensitivity to any component of this preparation. Children less than 12 years are also contraindicated
Pregnancy Pregnancy Category C. There are no or limited amount of data from the use of it Homatropine Eye Drops in pregnant women. Animal reproduction studies have not been conducted with homatropine hydrobromide. Animal studies are insufficient with respect to reproductive toxicity. It is also not known whether homatropine hydrobromide can cause foetal harm when administered to a pregnant woman or can affect reproduction capacity. Homatropine hydrobromide should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. However,homatropine and other antimuscarinic agents have been shown to adversely affect lactation in preclinical and in clinical studies. Therefore,it Homatropine Eye Drops should not be used during breast feeding.
Systemic homatropine toxicity may occur following topical use, particularly in children. It is manifested
by flushing and dryness of the skin (a rash may be present in children), blurred vision, a rapid and
irregular pulse, fever, abdominal distention in infants, convulsions, mental aberration (hallucinosis) and
loss of neuro-muscular coordination. In severe cases, central nervous system depression, circulatory
and respiratory failure, paralytic ileus, confusion, psychoses, agitation, delusions, delirium, and paranoia
may be encountered as well as tachycardia, dysrhythmias, hypertension, seizures, coma and death.
Atropine poisoning, although distressing, is rarely fatal even with large doses of atropine, and is selflimited if the cause is recognized and the homatropine medication is discontinued. Treatment includes
symptomatic and supportive measures including maintaining a patent airway and assisting respiration if
needed. Treat hyperthermia, coma and seizures if they occur (1). In infants and children, the body
surface must be kept moist. Excitement may be controlled by diazepam or a short-acting barbiturate.
For ingestion, activated charcoal can be used to prevent drug absorption. If necessary ipecac or
another cathartic may be useful for drug removal during initial treatment (1,2). Physostigmine is used
as an antidote to the systemic effects of atropine and may be administered parenterally to provide
more prompt relief of intoxication. Parenteral physostigmine may be particularly useful in cases of
pronounced hallucinations, agitation in which a patient may be dangerous to himself or others,
arrhythmias resulting in uncontrolled hemodynamic instability, and intractable seizures
Store in a cool & dry place, protect from light. Do not use longer than 30 days after first opening. Keep out of the reach of children.
.png&w=384&q=75)